Search Results

There are 13430 results for: content related to: Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab

  1. You have free access to this content
    Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

    Cancer

    Volume 121, Issue 7, April 1, 2015, Pages: 997–1007, Kathryn M. Field, Justin T. Jordan, Patrick Y. Wen, Mark A. Rosenthal and David A. Reardon

    Version of Record online : 26 SEP 2014, DOI: 10.1002/cncr.28935

  2. You have free access to this content
    Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer

    Cancer

    Volume 119, Issue 20, 15 October 2013, Pages: 3653–3661, Jason C. Barnett, Angeles Alvarez Secord, David E. Cohn, Charles A. Leath III, Evan R. Myers and Laura J. Havrilesky

    Version of Record online : 6 AUG 2013, DOI: 10.1002/cncr.28283

  3. You have free access to this content
    Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

    Cancer

    Volume 121, Issue 9, May 1, 2015, Pages: 1456–1462, Jim Zhong, Arif N. Ali, Alfredo D. Voloschin, Yuan Liu, Walter J. Curran Jr, Ian R. Crocker and Hui-Kuo G. Shu

    Version of Record online : 29 DEC 2014, DOI: 10.1002/cncr.29234

  4. You have free access to this content
    Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab

    Cancer

    Volume 120, Issue 12, 15 June 2014, Pages: 1780–1786, Shubham Pant, Ludmila K. Martin, Susan Geyer, Lai Wei, Katherine Van Loon, Nilli Sommovilla, Mark Zalupski, Renuka Iyer, David Fogelman, Andrew H. Ko and Tanios Bekaii-Saab

    Version of Record online : 13 MAR 2014, DOI: 10.1002/cncr.28648

  5. You have free access to this content
    Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study

    Cancer

    Volume 119, Issue 14, 15 July 2013, Pages: 2555–2563, Jeffrey R. Infante, Tony R. Reid, Allen L. Cohn, William J. Edenfield, Terrence P. Cescon, John T. Hamm, Imtiaz A. Malik, Thomas A. Rado, Philip J. McGee, Donald A. Richards, Jamal Tarazi, Brad Rosbrook, Sinil Kim and Thomas H. Cartwright

    Version of Record online : 19 APR 2013, DOI: 10.1002/cncr.28112

  6. You have free access to this content
    Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

    Cancer

    Volume 121, Issue 4, February 15, 2015, Pages: 502–516, Jayson I. L. Bastien, Katharine A. McNeill and Howard A. Fine

    Version of Record online : 23 SEP 2014, DOI: 10.1002/cncr.28968

  7. You have free access to this content
    Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non–small cell lung cancer

    Cancer

    Volume 119, Issue 12, 15 June 2013, Pages: 2275–2281, Yoshiko Urata, Isamu Okamoto, Masayuki Takeda, Yoshihiro Hattori, Keiko Okuno, Temiko Shimada, Takayasu Kurata, Hiroyasu Kaneda, Masaki Miyazaki, Masaaki Terashima, Kaoru Tanaka, Satoshi Morita, Kazuhiko Nakagawa, Shunichi Negoro and Miyako Satouchi

    Version of Record online : 4 APR 2013, DOI: 10.1002/cncr.28048

  8. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial

    Cancer

    Volume 122, Issue 7, April 1, 2016, Pages: 1050–1059, Masayuki Takeda, Takeharu Yamanaka, Takashi Seto, Hidetoshi Hayashi, Koichi Azuma, Morihito Okada, Shunichi Sugawara, Haruko Daga, Tomonori Hirashima, Kimio Yonesaka, Yoshiko Urata, Haruyasu Murakami, Haruhiro Saito, Akihito Kubo, Toshiyuki Sawa, Eiji Miyahara, Naoyuki Nogami, Kazuhiko Nakagawa, Yoichi Nakanishi and Isamu Okamoto

    Version of Record online : 1 FEB 2016, DOI: 10.1002/cncr.29893

  9. You have free access to this content
    Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11)

    Cancer

    Volume 119, Issue 23, 1 December 2013, Pages: 4180–4187, Jason Fangusaro, Sridharan Gururangan, Tina Young Poussaint, Roger E. McLendon, Arzu Onar-Thomas, Katherine E. Warren, Shengjie Wu, Roger J. Packer, Anu Banerjee, Richard J. Gilbertson, Regina Jakacki, Amar Gajjar, Stewart Goldman, Ian F. Pollack, Henry S. Friedman, James M. Boyett, Larry E. Kun and Maryam Fouladi

    Version of Record online : 19 SEP 2013, DOI: 10.1002/cncr.28343

  10. You have free access to this content
    Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis

    Cancer

    Volume 119, Issue 19, 1 October 2013, Pages: 3489–3495, Derek R. Johnson, Heather E. Leeper and Joon H. Uhm

    Version of Record online : 18 JUL 2013, DOI: 10.1002/cncr.28259

  11. You have free access to this content
    Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

    Cancer

    Volume 120, Issue 14, 15 July 2014, Pages: 2164–2173, David S. Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Siqing Fu, Stacy L. Moulder, Sarina Piha-Paul, Apostolia M. Tsimberidou, YueJin Wen, Kirk S. Culotta, Kenna Anderes, Darren W. Davis, Wen Liu, Goldy C. George, Luis H. Camacho, Susan Percy Ivy and Razelle Kurzrock

    Version of Record online : 17 APR 2014, DOI: 10.1002/cncr.28701

  12. You have free access to this content
    Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

    Cancer

    Volume 121, Issue 7, April 1, 2015, Pages: 1025–1031, Jai N. Patel, Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Kouros Owzar, Susan Halabi, Mark J. Ratain, Paula N. Friedman, Eric J. Small, Michael A. Carducci, John F. Mahoney, Michael J. Kelley, Michael J. Morris, William K. Kelly and Howard L. McLeod

    Version of Record online : 21 NOV 2014, DOI: 10.1002/cncr.29169

  13. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

    Cancer

    Volume 122, Issue 9, May 1, 2016, Pages: 1434–1443, Didier Meulendijks, Jan Willem B. de Groot, Maartje Los, James E. Boers, Laurens V. Beerepoot, Marco B. Polee, Aart Beeker, Johanna E.A. Portielje, Swan H. Goey, Robert S. de Jong, Steven A.L.W. Vanhoutvin, Maria Kuiper, Karolina Sikorska, Dick Pluim, Jos H. Beijnen, Jan H.M. Schellens, Cecile Grootscholten, Margot E.T. Tesselaar and Annemieke Cats

    Version of Record online : 11 MAR 2016, DOI: 10.1002/cncr.29864

  14. You have free access to this content
    Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group

    Cancer

    Volume 120, Issue 3, 1 February 2014, Pages: 344–351, Jubilee Brown, William E. Brady, Julian Schink, Linda Van Le, Mario Leitao, S. Diane Yamada, Koen de Geest and David M. Gershenson

    Version of Record online : 24 OCT 2013, DOI: 10.1002/cncr.28421

  15. Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001)

    Cancer

    Volume 122, Issue 5, March 1, 2016, Pages: 740–747, Wei Ou, Ning Li, Si-Yu Wang, Jian Li, Qian-Wen Liu, Qun-Ai Huang and Bao-Xiao Wang

    Version of Record online : 23 DEC 2015, DOI: 10.1002/cncr.29800

  16. You have free access to this content
    FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

    Cancer

    Volume 120, Issue 22, November 15, 2014, Pages: 3494–3501, Preetesh Jain, Hun Ju Lee, Wei Qiao, William Wierda, Ohad Benjamini, Jan Burger, Alessandra Ferrajoli, Zeev Estrov, Hagop Kantarjian, Michael Keating and Susan O'Brien

    Version of Record online : 15 JUL 2014, DOI: 10.1002/cncr.28910

  17. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study

    Cancer

    Volume 122, Issue 20, October 15, 2016, Pages: 3119–3126, Jean-Marc Ferrero, Anne-Claire Hardy-Bessard, Olivier Capitain, Alain Lortholary, Bruno Salles, Philippe Follana, Robert Herve, Mathilde Deblock, Jérôme Dauba, Mustapha Atlassi and Rémy Largillier

    Version of Record online : 14 JUL 2016, DOI: 10.1002/cncr.30170

  18. You have free access to this content
    Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas

    Cancer

    Volume 116, Issue 17, 1 September 2010, Pages: 3988–3999, Marc C. Chamberlain

    Version of Record online : 19 AUG 2010, DOI: 10.1002/cncr.25256

  19. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial

    Cancer

    Volume 122, Issue 19, October 1, 2016, Pages: 2961–2970, Jan C. Drooger, Harm van Tinteren, Steffen M. de Groot, Albert J. ten Tije, Hiltje de Graaf, Johanneke E. A. Portielje, Agnes Jager, Aafke Honkoop, Sabine C. Linn, Judith R. Kroep, Frans L. G. Erdkamp, Paul Hamberg, Alex L. T. Imholz, Quirine C. van Rossum-Schornagel, Joan B. Heijns, A. Elise van Leeuwen-Stok and Stefan Sleijfer

    Version of Record online : 17 JUN 2016, DOI: 10.1002/cncr.30141

  20. You have free access to this content
    NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer

    Cancer

    Volume 121, Issue 13, July 1, 2015, Pages: 2156–2163, Akila N. Viswanathan, Jennifer Moughan, Brigitte E. Miller, Ying Xiao, Anuja Jhingran, Lorraine Portelance, Walter R. Bosch, Ursula A. Matulonis, Neil S. Horowitz, Robert S. Mannel, Luis Souhami, Beth A. Erickson, Kathryn A. Winter, William Small Jr and David K. Gaffney

    Version of Record online : 6 APR 2015, DOI: 10.1002/cncr.29337